1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Age Related Functional Decline - Pipeline Review, H2 2014

Age Related Functional Decline - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 27 pages

Age Related Functional Decline - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Age Related Functional Decline - Pipeline Review, H2 2014’, provides an overview of the Age Related Functional Decline’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Age Related Functional Decline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Functional Decline and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Age Related Functional Decline
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Age Related Functional Decline and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Age Related Functional Decline products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Age Related Functional Decline pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Age Related Functional Decline
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Age Related Functional Decline pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Age Related Functional Decline - Pipeline Review, H2 2014
Table of Contents
Introduction 4
Global Markets Direct Report Coverage 4
Age Related Functional Decline Overview 5
Therapeutics Development 6
Pipeline Products for Age Related Functional Decline - Overview 6
Pipeline Products for Age Related Functional Decline - Comparative Analysis 7
Age Related Functional Decline - Therapeutics under Development by Companies 8
Age Related Functional Decline - Therapeutics under Investigation by Universities/Institutes 9
Age Related Functional Decline - Pipeline Products Glance 10
Early Stage Products 10
Age Related Functional Decline - Products under Development by Companies 11
Age Related Functional Decline - Products under Investigation by Universities/Institutes 12
Age Related Functional Decline - Companies Involved in Therapeutics Development 13
Chronos Therapeutics Limited 13
TAmiRNA GmbH 14
Age Related Functional Decline - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Combination Products 16
Assessment by Target 17
Assessment by Mechanism of Action 18
Assessment by Molecule Type 19
Drug Profiles 20
CHR-1 - Drug Profile 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
CHR-3 - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Drug for Frailty Disease - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
metformin + sirolimus - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Small Molecules for Age Related Diseases - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Age Related Functional Decline - Dormant Projects 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables

Number of Products under Development for Age Related Functional Decline, H2 2014 6
Number of Products under Development for Age Related Functional Decline - Comparative Analysis, H2 2014 7
Number of Products under Development by Companies, H2 2014 8
Number of Products under Investigation by Universities/Institutes, H2 2014 9
Comparative Analysis by Early Stage Development, H2 2014 10
Products under Development by Companies, H2 2014 11
Products under Investigation by Universities/Institutes, H2 2014 12
Age Related Functional Decline - Pipeline by Chronos Therapeutics Limited, H2 2014 13
Age Related Functional Decline - Pipeline by TAmiRNA GmbH, H2 2014 14
Assessment by Monotherapy Products, H2 2014 15
Assessment by Combination Products, H2 2014 16
Number of Products by Stage and Target, H2 2014 17
Number of Products by Stage and Mechanism of Action, H2 2014 18
Number of Products by Stage and Molecule Type, H2 2014 19
Age Related Functional Decline - Dormant Projects, H2 2014 25

List of Figures

Number of Products under Development for Age Related Functional Decline, H2 2014 6
Number of Products under Development for Age Related Functional Decline - Comparative Analysis, H2 2014 7
Number of Products under Development by Companies, H2 2014 8
Comparative Analysis by Early Stage Products, H2 2014 10
Assessment by Monotherapy Products, H2 2014 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.